Search

Your search keyword '"Turner, Amy S"' showing total 195 results
Start Over Author "Turner, Amy S"
195 results on '"Turner, Amy S"'

1. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

Author

Humphrey, Mary Beth, Russell, Linda, Danila, Maria I, Fink, Howard A, Guyatt, Gordon, Cannon, Michael, Caplan, Liron, Gore, Sara, Grossman, Jennifer, Hansen, Karen E, Lane, Nancy E, S., Nina, Magrey, Marina, McAlindon, Tim, Robinson, Angela Byun, Saha, Sumona, Womack, Charles, Abdulhadi, Basma, Charles, Julia F, Cheah, Jonathan TL, Chou, Sharon, Goyal, Itivrita, Haseltine, Katherine, Jackson, Lesley, Mirza, Reza, Moledina, Iram, Punni, Emma, Rinden, Tim, Turgunbaev, Marat, Wysham, Katherine, Turner, Amy S, and Uhl, Stacey

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Osteoporosis, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Management of diseases and conditions, 7.3 Management and decision making, Musculoskeletal, Good Health and Well Being, Adult, Child, Humans, United States, Rheumatology, Glucocorticoids, Bone Density, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveThe objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.MethodsAn updated systematic literature review was performed for clinical questions on nonpharmacologic, pharmacologic treatments, discontinuation of medications, and sequential therapy. Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the certainty of evidence. A Voting Panel achieved ≥70% consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsFor adults beginning or continuing >3 months of GC treatment, we strongly recommend as soon as possible after initiation of GCs, initial assessment of fracture risks with clinical fracture assessment, bone mineral density with vertebral fracture assessment or spinal x-ray, and Fracture Risk Assessment Tool if ≥40 years old. For adults at medium, high, or very high fracture risk, we strongly recommend pharmacologic treatment. Choice of oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs should be made by shared decision-making. Anabolic agents are conditionally recommended as initial therapy for those with high and very high fracture risk. Recommendations are made for special populations, including children, people with organ transplants, people who may become pregnant, and people receiving very high-dose GC treatment. New recommendations for both discontinuation of osteoporosis therapy and sequential therapies are included.ConclusionThis guideline provides direction for clinicians and patients making treatment decisions for management of GIOP. These recommendations should not be used to limit or deny access to therapies.

Published
2023

2. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Author

Bass, Anne R, Chakravarty, Eliza, Akl, Elie A, Bingham, Clifton O, Calabrese, Leonard, Cappelli, Laura C, Johnson, Sindhu R, Imundo, Lisa F, Winthrop, Kevin L, Arasaratnam, Reuben J, Baden, Lindsey R, Berard, Roberta, Bridges, S Louis, Cheah, Jonathan TL, Curtis, Jeffrey R, Ferguson, Polly J, Hakkarinen, Ida, Onel, Karen B, Schultz, Grayson, Sivaraman, Vidya, Smith, Benjamin J, Sparks, Jeffrey A, Vogel, Tiphanie P, Williams, Eleanor Anderson, Calabrese, Cassandra, Cunha, Joanne S, Fontanarosa, Joann, Gillispie‐Taylor, Miriah C, Gkrouzman, Elena, Iyer, Priyanka, Lakin, Kimberly S, Legge, Alexandra, Lo, Mindy S, Lockwood, Megan M, Sadun, Rebecca E, Singh, Namrata, Sullivan, Nancy, Tam, Herman, Turgunbaev, Marat, Turner, Amy S, and Reston, James

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Immunization, Prevention, Vaccine Related, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Good Health and Well Being, Child, Humans, United States, Rheumatology, Antirheumatic Agents, Musculoskeletal Diseases, Vaccination
Abstract

ObjectiveTo provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).MethodsThis guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required ≥70% agreement on both the direction and strength of each recommendation.ResultsThis guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy. Safe approaches to the use of live attenuated vaccines in patients taking immunosuppressive medications are also addressed. Most recommendations are conditional and had low quality of supporting evidence.ConclusionApplication of these recommendations should consider patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.

Published
2023

3. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3

Author

Henderson, Lauren A, Canna, Scott W, Friedman, Kevin G, Gorelik, Mark, Lapidus, Sivia K, Bassiri, Hamid, Behrens, Edward M, Kernan, Kate F, Schulert, Grant S, Seo, Philip, Son, Mary Beth F, Tremoulet, Adriana H, VanderPluym, Christina, Yeung, Rae SM, Mudano, Amy S, Turner, Amy S, Karp, David R, and Mehta, Jay J

Subjects
Pediatric, Infectious Diseases, Prevention, Pediatric Research Initiative, Emerging Infectious Diseases, Vaccine Related, Good Health and Well Being, Adult, COVID-19, Child, Humans, Rheumatology, SARS-CoV-2, Systemic Inflammatory Response Syndrome, United States, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectiveTo provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS-CoV-2 infection. Recommendations are also provided for children with hyperinflammation during COVID-19, the acute, infectious phase of SARS-CoV-2 infection.MethodsThe Task Force is composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting.ResultsThe guidance was approved in June 2020 and updated in November 2020 and October 2021, and consists of 41 final guidance statements accompanied by flow diagrams depicting the diagnostic pathway for MIS-C and recommendations for initial immunomodulatory treatment of MIS-C.ConclusionOur understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.

Published
2022

4. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Author

Fraenkel, Liana, Bathon, Joan M, England, Bryant R, St.Clair, E William, Arayssi, Thurayya, Carandang, Kristine, Deane, Kevin D, Genovese, Mark, Huston, Kent Kwas, Kerr, Gail, Kremer, Joel, Nakamura, Mary C, Russell, Linda A, Singh, Jasvinder A, Smith, Benjamin J, Sparks, Jeffrey A, Venkatachalam, Shilpa, Weinblatt, Michael E, Al‐Gibbawi, Mounir, Baker, Joshua F, Barbour, Kamil E, Barton, Jennifer L, Cappelli, Laura, Chamseddine, Fatimah, George, Michael, Johnson, Sindhu R, Kahale, Lara, Karam, Basil S, Khamis, Assem M, Navarro-Millán, Iris, Mirza, Reza, Schwab, Pascale, Singh, Namrata, Turgunbaev, Marat, Turner, Amy S, Yaacoub, Sally, and Akl, Elie A

Subjects
Arthritis, Clinical Research, Management of diseases and conditions, 7.3 Management and decision making, Inflammatory and immune system, Good Health and Well Being, Antirheumatic Agents, Arthritis, Rheumatoid, Clinical Decision-Making, Consensus, Decision Support Techniques, Humans, Remission Induction, Rheumatology, Treatment Outcome, Clinical Sciences, Public Health and Health Services, Psychology
Abstract

ObjectiveTo develop updated guidelines for the pharmacologic management of rheumatoid arthritis.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsThe guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).ConclusionThis clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities.

Published
2021

5. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective

Author

Hannon, Charles P., Goodman, Susan M., Austin, Matthew S., Yates, Adolph, Jr., Guyatt, Gordon, Aggarwal, Vinay K., Baker, Joshua F., Bass, Phyllis, Bekele, Delamo Isaac, Dass, Danielle, Ghomrawi, Hassan M.K., Jevsevar, David S., Kwoh, C. Kent, Lajam, Claudette M., Meng, Charis F., Moreland, Larry W., Suleiman, Linda I., Wolfstadt, Jesse, Bartosiak, Kimberly, Bedard, Nicholas A., Blevins, Jason L., Cohen-Rosenblum, Anna, Courtney, P. Maxwell, Fernandez-Ruiz, Ruth, Gausden, Elizabeth B., Ghosh, Nilasha, King, Lauren K., Meara, Alexa Simon, Mehta, Bella, Mirza, Reza, Rana, Adam J., Sullivan, Nancy, Turgunbaev, Marat, Wysham, Katherine D., Yip, Kevin, Yue, Linda, Zywiel, Michael G., Russell, Linda, Turner, Amy S., and Singh, Jasvinder A.

Published
2023
Full Text
View/download PDF

6. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2

Author

Henderson, Lauren A, Canna, Scott W, Friedman, Kevin G, Gorelik, Mark, Lapidus, Sivia K, Bassiri, Hamid, Behrens, Edward M, Ferris, Anne, Kernan, Kate F, Schulert, Grant S, Seo, Philip, Son, Mary Beth F, Tremoulet, Adriana H, Yeung, Rae SM, Mudano, Amy S, Turner, Amy S, Karp, David R, and Mehta, Jay J

Subjects
Prevention, Pediatric Research Initiative, Vaccine Related, Lung, Emerging Infectious Diseases, Pediatric, Infectious Diseases, Good Health and Well Being, Adolescent, Advisory Committees, Anticoagulants, Antirheumatic Agents, COVID-19, Child, Child, Preschool, Delphi Technique, Diagnosis, Differential, Glucocorticoids, Humans, Immunoglobulins, Intravenous, Immunologic Factors, Infant, Infant, Newborn, Inflammation, Interleukin 1 Receptor Antagonist Protein, Mucocutaneous Lymph Node Syndrome, Platelet Aggregation Inhibitors, Rheumatology, SARS-CoV-2, Systemic Inflammatory Response Syndrome, Young Adult, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectiveTo provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recommendations are also provided for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection.MethodsThe Task Force was composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting.ResultsThe first version of the guidance was approved in June 2020, and consisted of 40 final guidance statements accompanied by a flow diagram depicting the diagnostic pathway for MIS-C. The document was revised in November 2020, and a new flow diagram with recommendations for initial immunomodulatory treatment of MIS-C was added.ConclusionOur understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.

Published
2021

7. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1

Author

Henderson, Lauren A, Canna, Scott W, Friedman, Kevin G, Gorelik, Mark, Lapidus, Sivia K, Bassiri, Hamid, Behrens, Edward M, Ferris, Anne, Kernan, Kate F, Schulert, Grant S, Seo, Philip, Son, Mary Beth F, Tremoulet, Adriana H, Yeung, Rae SM, Mudano, Amy S, Turner, Amy S, Karp, David R, and Mehta, Jay J

Subjects
Emerging Infectious Diseases, Prevention, Pediatric, Lung, Infectious Diseases, Good Health and Well Being, COVID-19, Consensus, Humans, Systemic Inflammatory Response Syndrome, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectiveTo provide guidance on the management of multisystem inflammatory syndrome in children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and to provide recommendations for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection.MethodsA multidisciplinary task force was convened by the American College of Rheumatology (ACR) to provide guidance on the management of MIS-C associated with SARS-CoV-2 and hyperinflammation in COVID-19. The task force was composed of 9 pediatric rheumatologists, 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved 2 rounds of anonymous voting and 2 webinars. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate), and consensus was rated as low, moderate, or high based on dispersion of the votes along the numeric scale. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, as prespecified prior to voting.ResultsThe ACR task force approved a total of 128 guidance statements addressing the management of MIS-C and hyperinflammation in pediatric COVID-19. These statements were refined into 40 final clinical guidance statements, accompanied by a flow diagram depicting the diagnostic pathway for MIS-C.ConclusionOur understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. The guidance provided in this "living document" reflects currently available evidence, coupled with expert opinion, and will be revised as further evidence becomes available.

Published
2020

8. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Author

Kolasinski, Sharon L, Neogi, Tuhina, Hochberg, Marc C, Oatis, Carol, Guyatt, Gordon, Block, Joel, Callahan, Leigh, Copenhaver, Cindy, Dodge, Carole, Felson, David, Gellar, Kathleen, Harvey, William F, Hawker, Gillian, Herzig, Edward, Kwoh, C Kent, Nelson, Amanda E, Samuels, Jonathan, Scanzello, Carla, White, Daniel, Wise, Barton, Altman, Roy D, DiRenzo, Dana, Fontanarosa, Joann, Giradi, Gina, Ishimori, Mariko, Misra, Devyani, Shah, Amit Aakash, Shmagel, Anna K, Thoma, Louise M, Turgunbaev, Marat, Turner, Amy S, and Reston, James

Subjects
Clinical Research, Behavioral and Social Science, Chronic Pain, Complementary and Integrative Health, Osteoarthritis, Arthritis, Pain Research, Mind and Body, Rehabilitation, Prevention, Aging, Musculoskeletal, Hand Joints, Humans, Osteoarthritis, Hip, Osteoarthritis, Knee, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectiveTo develop an evidence-based guideline for the comprehensive management of osteoarthritis (OA) as a collaboration between the American College of Rheumatology (ACR) and the Arthritis Foundation, updating the 2012 ACR recommendations for the management of hand, hip, and knee OA.MethodsWe identified clinically relevant population, intervention, comparator, outcomes questions and critical outcomes in OA. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available educational, behavioral, psychosocial, physical, mind-body, and pharmacologic therapies for OA. Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. A Voting Panel, including rheumatologists, an internist, physical and occupational therapists, and patients, achieved consensus on the recommendations.ResultsBased on the available evidence, either strong or conditional recommendations were made for or against the approaches evaluated. Strong recommendations were made for exercise, weight loss in patients with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, hand orthoses for first carpometacarpal (CMC) joint OA, tibiofemoral bracing for tibiofemoral knee OA, topical nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA, oral NSAIDs, and intraarticular glucocorticoid injections for knee OA. Conditional recommendations were made for balance exercises, yoga, cognitive behavioral therapy, kinesiotaping for first CMC OA, orthoses for hand joints other than the first CMC joint, patellofemoral bracing for patellofemoral knee OA, acupuncture, thermal modalities, radiofrequency ablation for knee OA, topical NSAIDs, intraarticular steroid injections and chondroitin sulfate for hand OA, topical capsaicin for knee OA, acetaminophen, duloxetine, and tramadol.ConclusionThis guideline provides direction for clinicians and patients making treatment decisions for the management of OA. Clinicians and patients should engage in shared decision-making that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

Published
2020

9. Development of an international glossary for clinical guidelines collaboration

Author

Christensen, Rachel E., Yi, Michael D., Kang, Bianca Y., Ibrahim, Sarah A., Anvery, Noor, Dirr, McKenzie, Adams, Stephanie, Amer, Yasser S., Bisdorff, Alexandre, Bradfield, Lisa, Brown, Steve, Earley, Amy, Fatheree, Lisa A., Fayoux, Pierre, Getchius, Thomas, Ginex, Pamela, Graham, Amanda, Green, Courtney R., Gresele, Paolo, Hanson, Helen, Haynes, Norrisa, Hegedüs, Laszlo, Hussein, Heba, Jakhmola, Priya, Kantorova, Lucia, Krishnasamy, Rathika, Krist, Alex, Landry, Gregory, Lease, Erika D., Ley, Luis, Marsden, Gemma, Meek, Tim, Meremikwu, Martin, Moga, Carmen, Mokrane, Saphia, Mujoomdar, Amol, Newton, Skye, O'Flynn, Norma, Perkins, Gavin D., Smith, Emma-Jane, Prematunge, Chatura, Rychert, Jenna, Saraco, Mindy, Schünemann, Holger J., Senerth, Emily, Sinclair, Alan, Shwayder, James, Stec, Carla, Tanni, Suzana, Taske, Nichole, Temple-Smolkin, Robyn L., Thomas, Louise, Thomas, Sherene, Tonnessen, Britt, Turner, Amy S., Van Dam, Anne, van Doormaal, Mitchell, Wan, Yung Liang, Ventura, Christina B., McFarlane, Emma, Morgan, Rebecca L., Ogunremi, Toju, and Alam, Murad

Published
2023
Full Text
View/download PDF

10. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Author

Goodman, Susan M., Springer, Bryan D., Chen, Antonia F., Davis, Marshall, Fernandez, David R., Figgie, Mark, Finlayson, Heather, George, Michael D., Giles, Jon T., Gilliland, Jeremy, Klatt, Brian, MacKenzie, Ronald, Michaud, Kaleb, Miller, Andy, Russell, Linda, Sah, Alexander, Abdel, Matthew P., Johnson, Beverly, Mandl, Lisa A., Sculco, Peter, Turgunbaev, Marat, Turner, Amy S., Yates, Adolph, Jr., and Singh, Jasvinder A.

Published
2022
Full Text
View/download PDF

12. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Author

Bass, Anne R., Chakravarty, Eliza, Akl, Elie A., Bingham, Clifton O., Calabrese, Leonard, Cappelli, Laura C., Johnson, Sindhu R., Imundo, Lisa F., Winthrop, Kevin L., Arasaratnam, Reuben J., Baden, Lindsey R., Berard, Roberta, Bridges, S. Louis, Jr., Cheah, Jonathan T. L., Curtis, Jeffrey R., Ferguson, Polly J., Hakkarinen, Ida, Onel, Karen B., Schultz, Grayson, Sivaraman, Vidya, Smith, Benjamin J., Sparks, Jeffrey A., Vogel, Tiphanie P., Williams, Eleanor Anderson, Calabrese, Cassandra, Cunha, Joanne S., Fontanarosa, Joann, Gillispie‐Taylor, Miriah C., Gkrouzman, Elena, Iyer, Priyanka, Lakin, Kimberly S., Legge, Alexandra, Lo, Mindy S., Lockwood, Megan M., Sadun, Rebecca E., Singh, Namrata, Sullivan, Nancy, Tam, Herman, Turgunbaev, Marat, Turner, Amy S., and Reston, James

Published
2023
Full Text
View/download PDF

13. Corrigendum to “Development of an international glossary for clinical guidelines collaboration” “[Journal of Clinical Epidemiology 158 (2023) 84-91]”

Author

Christensen, Rachel E., Yi, Michael D., Kang, Bianca Y., Ibrahim, Sarah A., Anvery, Noor, Dirr, McKenzie, Adams, Stephanie, Amer, Yasser S., Bisdorff, Alexandre, Bradfield, Lisa, Brown, Steve, Earley, Amy, Fatheree, Lisa A., Fayoux, Pierre, Getchius, Thomas, Ginex, Pamela, Graham, Amanda, Green, Courtney R., Gresele, Paolo, Hanson, Helen, Haynes, Norrisa, Hegedüs, Laszlo, Hussein, Heba, Jakhmola, Priya, Kantorova, Lucia, Krishnasamy, Rathika, Krist, Alex, Landry, Gregory, Lease, Erika D., Ley, Luis, Marsden, Gemma, Meek, Tim, Meremikwu, Martin, Moga, Carmen, Mokrane, Saphia, Mujoomdar, Amol, Newton, Skye, O'Flynn, Norma, Perkins, Gavin D., Smith, Emma-Jane, Prematunge, Chatura, Rychert, Jenna, Saraco, Mindy, Schünemann, Holger J., Senerth, Emily, Sinclair, Alan, Shwayder, James, Stec, Carla, Tanni, Suzana, Taske, Nichole, Temple-Smolkin, Robyn L., Thomas, Louise, Thomas, Sherene, Tonnessen, Britt, Turner, Amy S., Van Dam, Anne, van Doormaal, Mitchell, Wan, Yung Liang, Ventura, Christina B., McFarlane, Emma, Morgan, Rebecca L., Ogunremi, Toju, and Alam, Murad

Published
2024
Full Text
View/download PDF

14. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

Author

Humphrey, Mary Beth, primary, Russell, Linda, additional, Danila, Maria I., additional, Fink, Howard A., additional, Guyatt, Gordon, additional, Cannon, Michael, additional, Caplan, Liron, additional, Gore, Sara, additional, Grossman, Jennifer, additional, Hansen, Karen E., additional, Lane, Nancy E., additional, Ma, Nina S., additional, Magrey, Marina, additional, McAlindon, Tim, additional, Robinson, Angela Byun, additional, Saha, Sumona, additional, Womack, Charles, additional, Abdulhadi, Basma, additional, Charles, Julia F., additional, Cheah, Jonathan T. L., additional, Chou, Sharon, additional, Goyal, Itivrita, additional, Haseltine, Katherine, additional, Jackson, Lesley, additional, Mirza, Reza, additional, Moledina, Iram, additional, Punni, Emma, additional, Rinden, Tim, additional, Turgunbaev, Marat, additional, Wysham, Katherine, additional, Turner, Amy S., additional, and Uhl, Stacey, additional

Published
2023
Full Text
View/download PDF

16. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective

Author

Hannon, Charles P., primary, Goodman, Susan M., additional, Austin, Matthew S., additional, Yates, Adolph, additional, Guyatt, Gordon, additional, Aggarwal, Vinay K., additional, Baker, Joshua F., additional, Bass, Phyllis, additional, Bekele, Delamo Isaac, additional, Dass, Danielle, additional, Ghomrawi, Hassan M. K., additional, Jevsevar, David S., additional, Kwoh, C. Kent, additional, Lajam, Claudette M., additional, Meng, Charis F., additional, Moreland, Larry W., additional, Suleiman, Linda I., additional, Wolfstadt, Jesse, additional, Bartosiak, Kimberly, additional, Bedard, Nicholas A., additional, Blevins, Jason L., additional, Cohen‐Rosenblum, Anna, additional, Courtney, P. Maxwell, additional, Fernandez‐Ruiz, Ruth, additional, Gausden, Elizabeth B., additional, Ghosh, Nilasha, additional, King, Lauren K., additional, Meara, Alexa Simon, additional, Mehta, Bella, additional, Mirza, Reza, additional, Rana, Adam J., additional, Sullivan, Nancy, additional, Turgunbaev, Marat, additional, Wysham, Katherine D., additional, Yip, Kevin, additional, Yue, Linda, additional, Zywiel, Michael G., additional, Russell, Linda, additional, Turner, Amy S., additional, and Singh, Jasvinder A., additional

Published
2023
Full Text
View/download PDF

17. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

Author

England, Bryant R., primary, Smith, Benjamin J., additional, Baker, Nancy A., additional, Barton, Jennifer L., additional, Oatis, Carol A., additional, Guyatt, Gordon, additional, Anandarajah, Allen, additional, Carandang, Kristine, additional, Chan, Karmela Kim, additional, Constien, Deb, additional, Davidson, Eileen, additional, Dodge, Carole V., additional, Bemis‐Dougherty, Anita, additional, Everett, Sotiria, additional, Fisher, Nadine, additional, Fraenkel, Liana, additional, Goodman, Susan M., additional, Lewis, Janet, additional, Menzies, Victoria, additional, Moreland, Larry W., additional, Navarro‐Millan, Iris, additional, Patterson, Sarah, additional, Phillips, Lawrence “Rick”, additional, Shah, Neha, additional, Singh, Namrata, additional, White, Daniel, additional, AlHeresh, Rawan, additional, Barbour, Kamil E., additional, Bye, Thomas, additional, Guglielmo, Dana, additional, Haberman, Rebecca, additional, Johnson, Tate, additional, Kleiner, Anatole, additional, Lane, Chris Y., additional, Li, Linda C., additional, Master, Hiral, additional, Pinto, Daniel, additional, Poole, Janet L., additional, Steinbarger, Kimberly, additional, Sztubinski, Daniel, additional, Thoma, Louise, additional, Tsaltskan, Vlad, additional, Turgunbaev, Marat, additional, Wells, Courtney, additional, Turner, Amy S., additional, and Treadwell, Jonathan R., additional

Published
2023
Full Text
View/download PDF

18. American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Gravallese, Ellen M., additional, Harpaz, Rafael, additional, Kroger, Andrew, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2022
Full Text
View/download PDF

19. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐SevereOsteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective

Author

Hannon, Charles P., Goodman, Susan M., Austin, Matthew S., Yates, Adolph, Guyatt, Gordon, Aggarwal, Vinay K., Baker, Joshua F., Bass, Phyllis, Bekele, Delamo Isaac, Dass, Danielle, Ghomrawi, Hassan M. K., Jevsevar, David S., Kwoh, C. Kent, Lajam, Claudette M., Meng, Charis F., Moreland, Larry W., Suleiman, Linda I., Wolfstadt, Jesse, Bartosiak, Kimberly, Bedard, Nicholas A., Blevins, Jason L., Cohen‐Rosenblum, Anna, Courtney, P. Maxwell, Fernandez‐Ruiz, Ruth, Gausden, Elizabeth B., Ghosh, Nilasha, King, Lauren K., Meara, Alexa Simon, Mehta, Bella, Mirza, Reza, Rana, Adam J., Sullivan, Nancy, Turgunbaev, Marat, Wysham, Katherine D., Yip, Kevin, Yue, Linda, Zywiel, Michael G., Russell, Linda, Turner, Amy S., and Singh, Jasvinder A.

Abstract

To develop evidence‐based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient‐important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who have previously attempted nonoperative therapy, and for whom nonoperative therapy was ineffective, and who have chosen to undergo elective hip or knee arthroplasty (collectively referred to as TJA). We developed 13 clinically relevant population, intervention, comparator, outcomes (PICO) questions. After a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of evidence (high, moderate, low, or very low), and evidence tables were created. A Voting Panel, including 13 physicians and patients, discussed the PICO questions until consensus was achieved on the direction (for/against) and strength (strong/conditional) of the recommendations. The panel conditionally recommended against delaying TJA to pursue additional nonoperative treatment including physical therapy, nonsteroidal antiinflammatory drugs, ambulatory aids, and intraarticular injections. It conditionally recommended delaying TJA for nicotine reduction or cessation. The panel conditionally recommended delay for better glycemic control for patients who have diabetes mellitus, although no specific measure or level was identified. There was consensus that obesity by itself was not a reason for delay, but that weight loss should be strongly encouraged, and the increase in operative risk should be discussed. The panel conditionally recommended against delay in patients who have severe deformity or bone loss, or in patients who have a neuropathic joint. Evidence for all recommendations was graded as low or very low quality. This guideline provides evidence‐based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient‐important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.

Published
2023
Full Text
View/download PDF

20. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

Author

Goodman, Susan M., primary, Springer, Bryan D., additional, Chen, Antonia F., additional, Davis, Marshall, additional, Fernandez, David R., additional, Figgie, Mark, additional, Finlayson, Heather, additional, George, Michael D., additional, Giles, Jon T., additional, Gililland, Jeremy, additional, Klatt, Brian, additional, MacKenzie, Ronald, additional, Michaud, Kaleb, additional, Miller, Andy, additional, Russell, Linda, additional, Sah, Alexander, additional, Abdel, Matthew P., additional, Johnson, Beverly, additional, Mandl, Lisa A., additional, Sculco, Peter, additional, Turgunbaev, Marat, additional, Turner, Amy S., additional, Yates, Adolph, additional, and Singh, Jasvinder A., additional

Published
2022
Full Text
View/download PDF

21. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

Author

England, Bryant R., Smith, Benjamin J., Baker, Nancy A., Barton, Jennifer L., Oatis, Carol A., Guyatt, Gordon, Anandarajah, Allen, Carandang, Kristine, Chan, Karmela Kim, Constien, Deb, Davidson, Eileen, Dodge, Carole V., Bemis‐Dougherty, Anita, Everett, Sotiria, Fisher, Nadine, Fraenkel, Liana, Goodman, Susan M., Lewis, Janet, Menzies, Victoria, Moreland, Larry W., Navarro‐Millan, Iris, Patterson, Sarah, Phillips, Lawrence “Rick”, Shah, Neha, Singh, Namrata, White, Daniel, AlHeresh, Rawan, Barbour, Kamil E., Bye, Thomas, Guglielmo, Dana, Haberman, Rebecca, Johnson, Tate, Kleiner, Anatole, Lane, Chris Y., Li, Linda C., Master, Hiral, Pinto, Daniel, Poole, Janet L., Steinbarger, Kimberly, Sztubinski, Daniel, Thoma, Louise, Tsaltskan, Vlad, Turgunbaev, Marat, Wells, Courtney, Turner, Amy S., and Treadwell, Jonathan R.

Abstract

To develop initial American College of Rheumatology (ACR) guidelines on the use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease‐modifying antirheumatic drugs (DMARDs) as part of an integrative management approach for people with rheumatoid arthritis (RA). An interprofessional guideline development group constructed clinically relevant Population, Intervention, Comparator, and Outcome (PICO) questions. A literature review team then completed a systematic literature review and applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to rate the certainty of evidence. An interprofessional Voting Panel (n = 20 participants) that included 3 individuals with RA achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. The Voting Panel achieved consensus on 28 recommendations for the use of integrative interventions in conjunction with DMARDs for the management of RA. Consistent engagement in exercise received a strong recommendation. Of 27 conditional recommendations, 4 pertained to exercise, 13 to rehabilitation, 3 to diet, and 7 to additional integrative interventions. These recommendations are specific to RA management, recognizing that other medical indications and general health benefits may exist for many of these interventions. This guideline provides initial ACR recommendations on integrative interventions for the management of RA to accompany DMARD treatments. The broad range of interventions included in these recommendations illustrates the importance of an interprofessional, team‐based approach to RA management. The conditional nature of most recommendations requires clinicians to engage persons with RA in shared decision‐making when applying these recommendations.

Published
2023
Full Text
View/download PDF

22. American College of Rheumatology Guidance forCOVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Gravallese, Ellen M., additional, Harpaz, Rafael, additional, Kroger, Andrew, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2022
Full Text
View/download PDF

23. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Author

Gorelik, Mark, primary, Chung, Sharon A., additional, Ardalan, Kaveh, additional, Binstadt, Bryce A., additional, Friedman, Kevin, additional, Hayward, Kristen, additional, Imundo, Lisa F., additional, Lapidus, Sivia K., additional, Kim, Susan, additional, Son, Mary Beth, additional, Sule, Sangeeta, additional, Tremoulet, Adriana H., additional, Van Mater, Heather, additional, Yildirim‐Toruner, Cagri, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2022
Full Text
View/download PDF

24. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

Author

Onel, Karen B., primary, Horton, Daniel B., additional, Lovell, Daniel J., additional, Shenoi, Susan, additional, Cuello, Carlos A., additional, Angeles‐Han, Sheila T., additional, Becker, Mara L., additional, Cron, Randy Q., additional, Feldman, Brian M., additional, Ferguson, Polly J., additional, Gewanter, Harry, additional, Guzman, Jaime, additional, Kimura, Yukiko, additional, Lee, Tzielan, additional, Murphy, Katherine, additional, Nigrovic, Peter A., additional, Ombrello, Michael J., additional, Rabinovich, C. Egla, additional, Tesher, Melissa, additional, Twilt, Marinka, additional, Klein‐Gitelman, Marisa, additional, Barbar‐Smiley, Fatima, additional, Cooper, Ashley M., additional, Edelheit, Barbara, additional, Gillispie‐Taylor, Miriah, additional, Hays, Kimberly, additional, Mannion, Melissa L., additional, Peterson, Rosemary, additional, Flanagan, Elaine, additional, Saad, Nadine, additional, Sullivan, Nancy, additional, Szymanski, Ann Marie, additional, Trachtman, Rebecca, additional, Turgunbaev, Marat, additional, Veiga, Keila, additional, Turner, Amy S., additional, and Reston, James T., additional

Published
2022
Full Text
View/download PDF

25. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

Author

Onel, Karen B., primary, Horton, Daniel B., additional, Lovell, Daniel J., additional, Shenoi, Susan, additional, Cuello, Carlos A., additional, Angeles‐Han, Sheila T., additional, Becker, Mara L., additional, Cron, Randy Q., additional, Feldman, Brian M., additional, Ferguson, Polly J., additional, Gewanter, Harry, additional, Guzman, Jaime, additional, Kimura, Yukiko, additional, Lee, Tzielan, additional, Murphy, Katherine, additional, Nigrovic, Peter A., additional, Ombrello, Michael J., additional, Rabinovich, C. Egla, additional, Tesher, Melissa, additional, Twilt, Marinka, additional, Klein‐Gitelman, Marisa, additional, Barbar‐Smiley, Fatima, additional, Cooper, Ashley M., additional, Edelheit, Barbara, additional, Gillispie‐Taylor, Miriah, additional, Hays, Kimberly, additional, Mannion, Melissa L., additional, Peterson, Rosemary, additional, Flanagan, Elaine, additional, Saad, Nadine, additional, Sullivan, Nancy, additional, Szymanski, Ann Marie, additional, Trachtman, Rebecca, additional, Turgunbaev, Marat, additional, Veiga, Keila, additional, Turner, Amy S., additional, and Reston, James T., additional

Published
2022
Full Text
View/download PDF

26. Erratum to “2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective” [The Journal of Arthroplasty 38 (2023) 2193-2201]

Author

Hannon, Charles P., Goodman, Susan M., Austin, Matthew S., Yates, Adolph, Jr., Guyatt, Gordon, Aggarwal, Vinay K., Baker, Joshua F., Bass, Phyllis, Bekele, Delamo Isaac, Dass, Danielle, Ghomrawi, Hassan M.K., Jevsevar, David S., Kwoh, C. Kent, Lajam, Claudette M., Meng, Charis F., Moreland, Larry W., Suleiman, Linda I., Wolfstadt, Jesse, Bartosiak, Kimberly, Bedard, Nicholas A., Blevins, Jason L., Cohen-Rosenblum, Anna, Courtney, P. Maxwell, Fernandez-Ruiz, Ruth, Gausden, Elizabeth B., Ghosh, Nilasha, King, Lauren K., Meara, Alexa Simon, Mehta, Bella, Mirza, Reza, Rana, Adam J., Sullivan, Nancy, Turgunbaev, Marat, Wysham, Katherine D., Yip, Kevin, Yue, Linda, Zywiel, Michael G., Russell, Linda, Turner, Amy S., and Singh, Jasvinder A.

Published
2024
Full Text
View/download PDF

27. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5.

Author

Curtis, Jeffrey R., Johnson, Sindhu R., Anthony, Donald D., Arasaratnam, Reuben J., Baden, Lindsey R., Bass, Anne R., Calabrese, Cassandra, Gravallese, Ellen M., Harpaz, Rafael, Kroger, Andrew, Sadun, Rebecca E., Turner, Amy S., Williams, Eleanor Anderson, and Mikuls, Ted R.

Subjects
MUSCULOSKELETAL system diseases, CONSENSUS (Social sciences), IMMUNIZATION, COVID-19 vaccines, TIME, PUBLIC health, VACCINE effectiveness, DESCRIPTIVE statistics, RHEUMATISM, LITERATURE reviews, PATIENT care, DELPHI method, PATIENT safety
Abstract

Objective: To provide guidance to rheumatology providers on the use of COVID‐19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious diseases specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Gravallese, Ellen M., additional, Harpaz, Rafael, additional, Kroger, Andrew, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2021
Full Text
View/download PDF

29. Using Parallel Streams of Evidence to Inform Guideline Development: The Case of the 2021 American College of Rheumatology Management of Rheumatoid Arthritis Guideline

Author

Yaacoub, Sally, primary, Khamis, Assem M., additional, Al‐Gibbawi, Mounir, additional, Kahale, Lara A, additional, Bathon, Joan, additional, England, Bryant R, additional, Fraenkel, Liana, additional, St. Clair, E. William, additional, Turner, Amy S., additional, and Akl, Elie A., additional

Published
2021
Full Text
View/download PDF

30. Reply

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Gravallese, Ellen M., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Harpaz, Rafael, additional, Kroger, Andrew, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2021
Full Text
View/download PDF

31. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

Author

Maz, Mehrdad, primary, Chung, Sharon A., additional, Abril, Andy, additional, Langford, Carol A., additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

32. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Author

Chung, Sharon A., primary, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

33. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa

Author

Chung, Sharon A., primary, Gorelik, Mark, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

34. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Gravallese, Ellen M., additional, Harpaz, Rafael, additional, Kroger, Andrew, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2021
Full Text
View/download PDF

35. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2

Author

Wahezi, Dawn M., primary, Lo, Mindy S., additional, Rubinstein, Tamar B., additional, Ringold, Sarah, additional, Ardoin, Stacy P., additional, Downes, Kevin J., additional, Jones, Karla B., additional, Laxer, Ronald M., additional, Pellet Madan, Rebecca, additional, Mudano, Amy S., additional, Turner, Amy S., additional, Karp, David R., additional, and Mehta, Jay J., additional

Published
2021
Full Text
View/download PDF

36. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Author

Fraenkel, Liana, primary, Bathon, Joan M., additional, England, Bryant R., additional, St.Clair, E. William, additional, Arayssi, Thurayya, additional, Carandang, Kristine, additional, Deane, Kevin D., additional, Genovese, Mark, additional, Huston, Kent Kwas, additional, Kerr, Gail, additional, Kremer, Joel, additional, Nakamura, Mary C., additional, Russell, Linda A., additional, Singh, Jasvinder A., additional, Smith, Benjamin J., additional, Sparks, Jeffrey A., additional, Venkatachalam, Shilpa, additional, Weinblatt, Michael E., additional, Al‐Gibbawi, Mounir, additional, Baker, Joshua F., additional, Barbour, Kamil E., additional, Barton, Jennifer L., additional, Cappelli, Laura, additional, Chamseddine, Fatimah, additional, George, Michael, additional, Johnson, Sindhu R., additional, Kahale, Lara, additional, Karam, Basil S., additional, Khamis, Assem M., additional, Navarro-Millán, Iris, additional, Mirza, Reza, additional, Schwab, Pascale, additional, Singh, Namrata, additional, Turgunbaev, Marat, additional, Turner, Amy S., additional, Yaacoub, Sally, additional, and Akl, Elie A., additional

Published
2021
Full Text
View/download PDF

37. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1

Author

Curtis, Jeffrey R., primary, Johnson, Sindhu R., additional, Anthony, Donald D., additional, Arasaratnam, Reuben J., additional, Baden, Lindsey R., additional, Bass, Anne R., additional, Calabrese, Cassandra, additional, Gravallese, Ellen M., additional, Harpaz, Rafael, additional, Sadun, Rebecca E., additional, Turner, Amy S., additional, Williams, Eleanor Anderson, additional, and Mikuls, Ted R., additional

Published
2021
Full Text
View/download PDF

38. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.

Author

Curtis, Jeffrey R., Johnson, Sindhu R., Anthony, Donald D., Arasaratnam, Reuben J., Baden, Lindsey R., Bass, Anne R., Calabrese, Cassandra, Gravallese, Ellen M., Harpaz, Rafael, Kroger, Andrew, Sadun, Rebecca E., Turner, Amy S., Williams, Eleanor Anderson, and Mikuls, Ted R.

Subjects
DRUG therapy for rheumatism, MUSCULOSKELETAL system diseases, CONSENSUS (Social sciences), COVID-19, IMMUNIZATION, RHEUMATOLOGY, COVID-19 vaccines, TIME, MEDICAL protocols, IMMUNOTHERAPY, DELPHI method
Abstract

Objective: To provide guidance to rheumatology providers on the use of COVID‐19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. Results: Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. Conclusion: These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Reply

Author

Neogi, Tuhina, primary, Dalbeth, Nicola, additional, Mikuls, Ted R., additional, Turner, Amy S., additional, and FitzGerald, John D., additional

Published
2021
Full Text
View/download PDF

40. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1

Author

Wahezi, Dawn M., primary, Lo, Mindy S., additional, Rubinstein, Tamar B., additional, Ringold, Sarah, additional, Ardoin, Stacy P., additional, Downes, Kevin J., additional, Jones, Karla B., additional, Laxer, Ronald M., additional, Pellet Madan, Rebecca, additional, Mudano, Amy S., additional, Turner, Amy S., additional, Karp, David R., additional, and Mehta, Jay J., additional

Published
2020
Full Text
View/download PDF

41. 2020 American College of Rheumatology Guideline for the Management of Gout

Author

FitzGerald, John D., primary, Dalbeth, Nicola, additional, Mikuls, Ted, additional, Brignardello‐Petersen, Romina, additional, Guyatt, Gordon, additional, Abeles, Aryeh M., additional, Gelber, Allan C., additional, Harrold, Leslie R., additional, Khanna, Dinesh, additional, King, Charles, additional, Levy, Gerald, additional, Libbey, Caryn, additional, Mount, David, additional, Pillinger, Michael H., additional, Rosenthal, Ann, additional, Singh, Jasvinder A., additional, Sims, James Edward, additional, Smith, Benjamin J., additional, Wenger, Neil S., additional, Bae, Sangmee Sharon, additional, Danve, Abhijeet, additional, Khanna, Puja P., additional, Kim, Seoyoung C., additional, Lenert, Aleksander, additional, Poon, Samuel, additional, Qasim, Anila, additional, Sehra, Shiv T., additional, Sharma, Tarun Sudhir Kumar, additional, Toprover, Michael, additional, Turgunbaev, Marat, additional, Zeng, Linan, additional, Zhang, Mary Ann, additional, Turner, Amy S., additional, and Neogi, Tuhina, additional

Published
2020
Full Text
View/download PDF

42. Reply.

Author

England, Bryant R., Smith, Benjamin J., Baker, Nancy A., Barton, Jennifer L., Oatis, Carol A., and Turner, Amy S.

Subjects
EXERCISE therapy, OCCUPATIONAL therapists, PHYSICAL therapists, EXERCISE physiology, MEDICAL rehabilitation
Abstract

This document is a reply to Drs Khalil and Rathore's interest in the "2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis." The authors express gratitude for the interest and address several points raised by the doctors. They explain that the guideline included expertise from various stakeholders and acknowledge the need for more clarity in defining each team member's expertise. They also discuss the involvement of physiatrists in the guideline and the challenges of representing diverse patient characteristics. Additionally, they address the grouping of different types of exercise and the definition of rehabilitation. [Extracted from the article]

Published
2024
Full Text
View/download PDF

43. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Author

Kolasinski, Sharon L., primary, Neogi, Tuhina, additional, Hochberg, Marc C., additional, Oatis, Carol, additional, Guyatt, Gordon, additional, Block, Joel, additional, Callahan, Leigh, additional, Copenhaver, Cindy, additional, Dodge, Carole, additional, Felson, David, additional, Gellar, Kathleen, additional, Harvey, William F., additional, Hawker, Gillian, additional, Herzig, Edward, additional, Kwoh, C. Kent, additional, Nelson, Amanda E., additional, Samuels, Jonathan, additional, Scanzello, Carla, additional, White, Daniel, additional, Wise, Barton, additional, Altman, Roy D., additional, DiRenzo, Dana, additional, Fontanarosa, Joann, additional, Giradi, Gina, additional, Ishimori, Mariko, additional, Misra, Devyani, additional, Shah, Amit Aakash, additional, Shmagel, Anna K., additional, Thoma, Louise M., additional, Turgunbaev, Marat, additional, Turner, Amy S., additional, and Reston, James, additional

Published
2020
Full Text
View/download PDF

44. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

Author

Onel, Karen B., Horton, Daniel B., Lovell, Daniel J., Shenoi, Susan, Cuello, Carlos A., Angeles‐Han, Sheila T., Becker, Mara L., Cron, Randy Q., Feldman, Brian M., Ferguson, Polly J., Gewanter, Harry, Guzman, Jaime, Kimura, Yukiko, Lee, Tzielan, Murphy, Katherine, Nigrovic, Peter A., Ombrello, Michael J., Rabinovich, C. Egla, Tesher, Melissa, Twilt, Marinka, Klein‐Gitelman, Marisa, Barbar‐Smiley, Fatima, Cooper, Ashley M., Edelheit, Barbara, Gillispie‐Taylor, Miriah, Hays, Kimberly, Mannion, Melissa L., Peterson, Rosemary, Flanagan, Elaine, Saad, Nadine, Sullivan, Nancy, Szymanski, Ann Marie, Trachtman, Rebecca, Turgunbaev, Marat, Veiga, Keila, Turner, Amy S., and Reston, James T.

Abstract

To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided. We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Similar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.

Published
2022
Full Text
View/download PDF

45. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

Author

Onel, Karen B., Horton, Daniel B., Lovell, Daniel J., Shenoi, Susan, Cuello, Carlos A., Angeles‐Han, Sheila T., Becker, Mara L., Cron, Randy Q., Feldman, Brian M., Ferguson, Polly J., Gewanter, Harry, Guzman, Jaime, Kimura, Yukiko, Lee, Tzielan, Murphy, Katherine, Nigrovic, Peter A., Ombrello, Michael J., Rabinovich, C. Egla, Tesher, Melissa, Twilt, Marinka, Klein‐Gitelman, Marisa, Barbar‐Smiley, Fatima, Cooper, Ashley M., Edelheit, Barbara, Gillispie‐Taylor, Miriah, Hays, Kimberly, Mannion, Melissa L., Peterson, Rosemary, Flanagan, Elaine, Saad, Nadine, Sullivan, Nancy, Szymanski, Ann Marie, Trachtman, Rebecca, Turgunbaev, Marat, Veiga, Keila, Turner, Amy S., and Reston, James T.

Abstract

To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype. We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well‐balanced, age‐appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision‐making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional. This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.

Published
2022
Full Text
View/download PDF

46. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Author

Gorelik, Mark, Chung, Sharon A., Ardalan, Kaveh, Binstadt, Bryce A., Friedman, Kevin, Hayward, Kristen, Imundo, Lisa F., Lapidus, Sivia K., Kim, Susan, Son, Mary Beth, Sule, Sangeeta, Tremoulet, Adriana H., Van Mater, Heather, Yildirim‐Toruner, Cagri, Langford, Carol A., Maz, Mehrdad, Abril, Andy, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sundel, Robert P., Vitobaldi, Omar I., Warner, Ann, Byram, Kevin, Dua, Anisha B., Husainat, Nedaa, James, Karen E., Kalot, Mohamad, Lin, Yih Chang, Springer, Jason M., Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S., and Mustafa, Reem A.

Abstract

To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.

Published
2022
Full Text
View/download PDF

47. Supplemental Material, Singh_ART40726_Supplementary_Appendix_4_Study_Selection_Process - 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Author

Singh, Jasvinder A., Guyatt, Gordon, Ogdie, Alexis, Gladman, Dafna D., Deal, Chad, Deodhar, Atul, Dubreuil, Maureen, Dunham, Jonathan, M. Elaine Husni, Kenny, Sarah, Kwan-Morley, Jennifer, Lin, Janice, Marchetta, Paula, Mease, Philip J., Merola, Joseph F., Miner, Julie, Ritchlin, Christopher T., Siaton, Bernadette, Smith, Benjamin J., Voorhees, Abby S. Van, Jonsson, Anna Helena, Shah, Amit Aakash, Sullivan, Nancy, Turgunbaev, Marat, Coates, Laura C., Gottlieb, Alice, Magrey, Marina, W. Benjamin Nowell, Ana-Maria Orbai, Soumya M. Reddy, Scher, Jose U., Siegel, Evan, Siegel, Michael, Walsh, Jessica A., Turner, Amy S., and Reston, James

Subjects
Medicine
Abstract

Supplemental Material, Singh_ART40726_Supplementary_Appendix_4_Study_Selection_Process for 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis by Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M. Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip J. Mease, Joseph F. Merola, Julie Miner, Christopher T. Ritchlin, Bernadette Siaton, Benjamin J. Smith, Abby S. Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C. Coates, Alice Gottlieb, Marina Magrey, W. Benjamin Nowell, Ana-Maria Orbai, Soumya M. Reddy, Jose U. Scher, Evan Siegel, Michael Siegel, Jessica A. Walsh, Amy S. Turner, and James Reston in Journal of Psoriasis and Psoriatic Arthritis

Published
2018
Full Text
View/download PDF

48. Supplemental Material, Appendix_3_PsA_Search_Strategies - 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Author

Singh, Jasvinder A., Guyatt, Gordon, Ogdie, Alexis, Gladman, Dafna D., Deal, Chad, Deodhar, Atul, Dubreuil, Maureen, Dunham, Jonathan, M. Elaine Husni, Kenny, Sarah, Kwan-Morley, Jennifer, Lin, Janice, Marchetta, Paula, Mease, Philip J., Merola, Joseph F., Miner, Julie, Ritchlin, Christopher T., Siaton, Bernadette, Smith, Benjamin J., Voorhees, Abby S. Van, Jonsson, Anna Helena, Shah, Amit Aakash, Sullivan, Nancy, Turgunbaev, Marat, Coates, Laura C., Gottlieb, Alice, Magrey, Marina, W. Benjamin Nowell, Ana-Maria Orbai, Soumya M. Reddy, Scher, Jose U., Siegel, Evan, Siegel, Michael, Walsh, Jessica A., Turner, Amy S., and Reston, James

Subjects
Medicine
Abstract

Supplemental Material, Appendix_3_PsA_Search_Strategies for 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis by Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M. Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip J. Mease, Joseph F. Merola, Julie Miner, Christopher T. Ritchlin, Bernadette Siaton, Benjamin J. Smith, Abby S. Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C. Coates, Alice Gottlieb, Marina Magrey, W. Benjamin Nowell, Ana-Maria Orbai, Soumya M. Reddy, Jose U. Scher, Evan Siegel, Michael Siegel, Jessica A. Walsh, Amy S. Turner, and James Reston in Journal of Psoriasis and Psoriatic Arthritis

Published
2018
Full Text
View/download PDF

49. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

Author

Maz, Mehrdad, Chung, Sharon A., Abril, Andy, Langford, Carol A., Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., Vitobaldi, Omar I., Warner, Ann, Byram, Kevin, Dua, Anisha B., Husainat, Nedaa, James, Karen E., Kalot, Mohamad A., Lin, Yih Chang, Springer, Jason M., Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S., and Mustafa, Reem A.

Abstract

To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.

Published
2021
Full Text
View/download PDF

50. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Author

Singh, Jasvinder A., primary, Guyatt, Gordon, additional, Ogdie, Alexis, additional, Gladman, Dafna D., additional, Deal, Chad, additional, Deodhar, Atul, additional, Dubreuil, Maureen, additional, Dunham, Jonathan, additional, Husni, M. Elaine, additional, Kenny, Sarah, additional, Kwan-Morley, Jennifer, additional, Lin, Janice, additional, Marchetta, Paula, additional, Mease, Philip J., additional, Merola, Joseph F., additional, Miner, Julie, additional, Ritchlin, Christopher T., additional, Siaton, Bernadette, additional, Smith, Benjamin J., additional, Van Voorhees, Abby S., additional, Jonsson, Anna Helena, additional, Shah, Amit Aakash, additional, Sullivan, Nancy, additional, Turgunbaev, Marat, additional, Coates, Laura C., additional, Gottlieb, Alice, additional, Magrey, Marina, additional, Nowell, W. Benjamin, additional, Orbai, Ana-Maria, additional, Reddy, Soumya M., additional, Scher, Jose U., additional, Siegel, Evan, additional, Siegel, Michael, additional, Walsh, Jessica A., additional, Turner, Amy S., additional, and Reston, James, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results